Agios Pharmaceuticals Inc

Overview

Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company. The company focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia (AML); and TIBSOVO (ivosidenib), a prescription medicine used to treat adults with AML. Its pipeline products include AG-881, a pan-IDH mutant inhibitor intended for the treatment of hematologic malignancies and solid tumors; AG-270, an inhibitor of methionine adenosyltransferase 2a; and Mitapivat, a potent activator intended for the treatment of patients with pyruvate kinase deficiency. Agios is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
88 Sidney St, CAMBRIDGE, Massachusetts
Headquarters

United States of America

Contact

1 617 6498600

Website
www.agios.com
No of Employees

562

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

AGIO [NASD]

Revenue (2020)

$203 m

72.2% (2020 vs 2019)
Net Income (2020)

$-327 m

20.5% (2020 vs 2019)
Net Profit Margin

-161 %

53.8% (2020 vs 2019)
Market Cap *

$2,651 m

EPS *

$-4.7

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Agios Pharmaceuticals IncMerck & Co IncBayer AGAbbVie Inc
Key Information
Headquarters United States of America United States of America Germany United States of America
Headquarter City CAMBRIDGE KENILWORTH LEVERKUSEN NORTH CHICAGO
Headquarter State/Province Massachusetts New Jersey - Illinois
No. of Employees 562 74,000 99,439 48,000
Entity Type Public Public Public Public

Products & Services

Agios is involved in the production and distribution of investigational medicines. Key products of the company include the following:

Products
  • IDHIFA- IDH2 Inhibitor
  • TIBSOVO - IDH1 Inhibitor
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 New Products/Services In June, the company announced the launch of myAgios patient support services for people living…
2021 Others In June, the company submitted a new drug application to the US FDA for its…
2020 Contracts/Agreements In December, the company entered into an agreement to sell its oncology business to Les…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Agios Netherlands B.V.
Agios France SARL
Agios Securities Corporation
Agios Italy S.R.L.
Agios Limited
Agios International Sarl
Agios Germany Gmbh

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
21 Dec 2020 Les Laboratoires Servier Acquires Oncology Business from Agios Pharma Asset Transaction Les Laboratoires Servier SAS Agios Pharmaceuticals Inc
21 Sep 2020 Agios Pharmaceuticals Inc Enters Phase I Clinical Trial Agreement with Labcorp Drug Development for mitapivat sulfate (GDCT0400205) Contract Service Agreement Agios Pharmaceuticals Inc; Agios Pharmaceuticals Inc Labcorp Drug Development; Labcorp Drug Development
17 Jun 2020 Agios Pharmaceuticals Inc Enters Phase I Clinical Trial Agreement with Pharmaceutical Product Development LLC for mitapivat sulfate (GDCT0393220) Contract Service Agreement Agios Pharmaceuticals Inc; Agios Pharmaceuticals Inc Pharmaceutical Product Development LLC; Pharmaceutical Product Development LLC
12 Jun 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
09 Jun 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
06 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

29

Active Jobs

13

Posted

12

Closed

Job Trends

Latest Jobs

Job title Company Country
Scientist/Sr. Scientist, Metabolism Agios Pharmaceuticals Inc United States
Associate Director/Sr. Manager, Commercial Training Agios Pharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar